[HTML][HTML] Lutetium Lu 177 vipivotide tetraxetan: first approval
SJ Keam - Molecular diagnosis & therapy, 2022 - Springer
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
[HTML][HTML] Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
Radiation dosimetry in 177Lu-PSMA-617 therapy
Radionuclide therapy using the small molecule PSMA bound to the beta-emitting
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …
[HTML][HTML] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
N Mader, C Nguyen Ngoc, B Kirkgöze… - European Journal of …, 2023 - Springer
Purpose The currently used scheme for radioligand therapy (RLT) of patients with metastatic
castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [177Lu] …
castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [177Lu] …
[HTML][HTML] Pharmacological optimization of PSMA-based radioligand therapy
S van der Gaag, IH Bartelink, AN Vis, GL Burchell… - Biomedicines, 2022 - mdpi.com
Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …
Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177Lu-PSMA therapy of prostate cancer
Background and objective 177 Lu-labeled prostate-specific membrane antigen (PSMA)
radiopharmaceutical therapy (RPT) represents a pivotal advancement in addressing …
radiopharmaceutical therapy (RPT) represents a pivotal advancement in addressing …
[HTML][HTML] PSMA-targeted therapy for non-prostate cancers
Radioligand therapy (RLT) agents are demonstrating a crucial role in the clinical approach
to aggressive malignancies such as metastatic castrate-resistant prostate cancer (m-CRPC) …
to aggressive malignancies such as metastatic castrate-resistant prostate cancer (m-CRPC) …
[HTML][HTML] Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T
PE Hartrampf, FX Weinzierl, SE Serfling, MG Pomper… - Cancers, 2022 - mdpi.com
Simple Summary Radioligand therapy (RLT) with prostate-specific membrane antigen
(PSMA)-directed agents has shown remarkable results in patients with advanced prostate …
(PSMA)-directed agents has shown remarkable results in patients with advanced prostate …
[HTML][HTML] 2022 FDA TIDES (peptides and oligonucleotides) harvest
A total of 37 new drug entities were approved in 2022; although that year registered the
lowest number of drug approvals since 2016, the TIDES class consolidated its presence with …
lowest number of drug approvals since 2016, the TIDES class consolidated its presence with …